The effect of Neuragen PN(R) on neuropathic pain: a randomized, double blind, pl

[Guest guest]

BMC Complement Altern Med. 2010 May 20;10(1):22

The effect of Neuragen PN® on neuropathic pain: a randomized, double blind,

placebo controlled clinical trial.

Li L.

Abstract

BACKGROUND: A double blind, randomized, placebo controlled study to evaluate the

safety and efficacy of the naturally derived topical oil, " Neuragen PN® " for

the treatment of neuropathic pain. METHODS: Sixty participants with plantar

cutaneous (foot sole) pain due to all cause peripheral neuropathy were recruited

from the community. Each subject was randomly assigned to receive one of two

treatments (Neuragen PN® or placebo) per week in a crossover design. The

primary outcome measure was acute spontaneous pain level as reported on a visual

analog scale.

RESULTS: There was an overall pain reduction for both treatments from pre to

post application. As compared to the placebo, Neuragen PN® led to

significantly (p < .05) greater pain reduction. Fifty six of sixty subjects

(93.3%) receiving Neuragen PN® reported pain reduction within 30 minutes. This

reduction within 30 minutes occurred in only twenty one of sixty (35.0%)

subjects receiving the placebo. In a break out analysis of the diabetic only

subgroup, 94% of subjects in the Neuragen PN® group achieved pain reduction

within 30 minutes vs 11.0% of the placebo group. No adverse events were

observed.

CONCLUSIONS: This randomized, placebo controlled, clinical trial with crossover

design revealed that the naturally derived oil, Neuragen PN®, provided

significant relief from neuropathic pain in an all cause neuropathy group.

Participants with diabetes within this group experienced similar pain relief.